Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.
Cytokine Growth Factor Rev. 2021 Jun;59:1-8. doi: 10.1016/j.cytogfr.2021.02.001. Epub 2021 Feb 14.
During the Tenth Edition of the Annual Congress on "Anticancer Innovative Therapy" [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the roles of i] epigenetics, and in particular, chromatin modifiers, ii] cancer metabolism, iii] cancer stem cells [CSCs], iv] tumor cell signaling, and iv] the immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against CSCs, liposome-delivered miRNAs, tumor-specific CAR-T cells, and T-cell-based immunotherapy. Moreover, important evidence on possible mechanisms of resistance to these innovative therapies were also discussed, in particular with respect to resistance to ICB. Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term.
在第十届“抗癌创新疗法”年度大会上[米兰，2020 年 1 月 23-24 日]，免疫肿瘤学、表观遗传学、肿瘤细胞信号转导和癌症代谢领域的专家分享了他们在以下方面的最新知识：i]表观遗传学，特别是染色质修饰剂；ii]癌症代谢；iii]癌症干细胞[CSC]；iv]肿瘤细胞信号转导；以及 iv]免疫系统。提出的新型治疗方法包括表观遗传学药物、与 ICB 联合使用的细胞周期抑制剂、抗生素和其他非标签药物、针对 CSC 的小分子、脂质体递送的 miRNA、肿瘤特异性 CAR-T 细胞和基于 T 细胞的免疫疗法。此外，还讨论了这些创新疗法可能出现耐药的机制的重要证据，特别是针对 ICB 的耐药性。总的来说，本次会议为科学家和临床医生提供了对未来挑战和希望的广泛了解，以期在中短期合理改善癌症治疗。
